Corporate Office HQ

Medical

Hospira Corporate Office

Hospira is a pharmaceutical and medical device company.

The company was formed in 2004 when Abbot Laboratories spun-off its hospital products division. The name “Hospira” was chosen by a vote of the employees and is a combination of the words hospital, spirit, inspire, and the Latin word for hope, spero.

At the time of the spin-off, Hospira had 14 manufacturing sites, 14,000 employees, and $2.5 billion in sales annually.

Today Hospira produces mostly generic specialty injectable pharmaceuticals for cardiovascular, anesthesia, oncology, and anti-infective therapies as well as pre-filled syringes. The company also manufactures electronic drug pumps and infusion therapy devices. Customers include wholesalers, drug manufacturers, nursing centers, outpatient surgical care facilities, and hospitals.

Hospira trades publicly on the New York Stock exchange under the ticker symbol HSP, is a member of the S&P 500, is #606 in the Fortune 500, has 17,000 employees, and had $4.42 billion in revenue in 2013.

Hospira

Hospira is a pharmaceutical and medical device company.

The company was formed in 2004 when Abbot Laboratories spun-off its hospital products division. The name “Hospira” was chosen by a vote of the employees and is a combination of the words hospital, spirit, inspire, and the Latin word for hope, spero.

At the time of the spin-off, Hospira had 14 manufacturing sites, 14,000 employees, and $2.5 billion in sales annually.

History

Today Hospira produces mostly generic specialty injectable pharmaceuticals for cardiovascular, anesthesia, oncology, and anti-infective therapies as well as pre-filled syringes. The company also manufactures electronic drug pumps and infusion therapy devices. Customers include wholesalers, drug manufacturers, nursing centers, outpatient surgical care facilities, and hospitals.

Hospira trades publicly on the New York Stock exchange under the ticker symbol HSP, is a member of the S&P 500, is #606 in the Fortune 500, has 17,000 employees, and had $4.42 billion in revenue in 2013.

Forest Laboratories Corporate Office

Forest Laboratories was founded in 1956 as a small laboratory service company, helping pharmaceutical companies to create new drugs.

In 1977 the company changed its focus to marketing new and generic drugs, as the then-CEO Howard Solomon wanted to explore this more profitable side of the business.

One notable acquisition was Aerobid, and asthma drug, in 1986. At the time of purchase Aerobid had total sales of $2.3 million. By 1991 Forest had made the drug very profitable, with yearly revenue of $30 million.

Today Forest Laboratories develops and manufactures such drugs as Namenda for Alzheimer’s, Savella for fibromyalgia, Lexapro the antidepressant, Bystolic for hypertension, as well as generic and OTC (over-the-counter) drugs.

Until 2014 Forest was publicly traded on the New York Stock Exchange under the ticker symbol FRX. In 2014 the company was acquired by Actavis in a $25 billion deal.

 

Forest Laboratories

Forest Laboratories was founded in 1956 as a small laboratory service company, helping pharmaceutical companies to create new drugs.

In 1977 the company changed its focus to marketing new and generic drugs, as the then-CEO Howard Solomon wanted to explore this more profitable side of the business.

One notable acquisition was Aerobid, and asthma drug, in 1986. At the time of purchase Aerobid had total sales of $2.3 million. By 1991 Forest had made the drug very profitable, with yearly revenue of $30 million.

History

Today Forest Laboratories develops and manufactures such drugs as Namenda for Alzheimer’s, Savella for fibromyalgia, Lexapro the antidepressant, Bystolic for hypertension, as well as generic and OTC (over-the-counter) drugs.

Until 2014 Forest was publicly traded on the New York Stock Exchange under the ticker symbol FRX. In 2014 the company was acquired by Actavis in a $25 billion deal.

 

Zimmer Holdings Corporate Office

Zimmer Holdings  was founded in 1927 by Justin Zimmer in Warsaw, Indiana to produce aluminum splints. In the first year of production the company reached $160,000 in sales.

The company grew as an orthopedic developer and manufacturer and continually added new offerings to its product portfolio, such as internal bone fixation devices in the 1930’s and titanium-based implant devices in the 1950’s.

Today Zimmer Holdings continues to design and market orthopedic products, including implants used in knee and hip replacements, shoulder implants that restore function to arthritic joints, and tissue and bone grafting materials. The company also produces surgical products such as devices for wound cleansing.

Zimmer Holdings is traded publicly on the New York Stock Exchange under the ticker symbol ZMH, is a member of the S&P 500, is #531 in the Fortune 500, has 9,000 employees, and had $4.69 billion in revenue in 2013.

Zimmer Holdings

Zimmer Holdings  was founded in 1927 by Justin Zimmer in Warsaw, Indiana to produce aluminum splints. In the first year of production the company reached $160,000 in sales.

The company grew as an orthopedic developer and manufacturer and continually added new offerings to its product portfolio, such as internal bone fixation devices in the 1930’s and titanium-based implant devices in the 1950’s.

Today Zimmer Holdings continues to design and market orthopedic products, including implants used in knee and hip replacements, shoulder implants that restore function to arthritic joints, and tissue and bone grafting materials. The company also produces surgical products such as devices for wound cleansing.

History

Zimmer Holdings is traded publicly on the New York Stock Exchange under the ticker symbol ZMH, is a member of the S&P 500, is #531 in the Fortune 500, has 9,000 employees, and had $4.69 billion in revenue in 2013.

Kindred Healthcare Corporate Office

Kindred Healthcare is a healthcare services company that operates nursing homes, hospitals, and rehabilitation centers.

The company was founded in 1985 as Vencor, Inc.

Kindred operates in four divisions. The Transitional Care Hospital division provides long-term care to medically complex patients. The Nursing and Rehabilitation Services division operates nursing homes, rehabilitation centers, and assisted living centers.

Care Management provides hospice, home health, and private nursing in patients’ homes. RehabCare is Kindred’s division that provides hospital rehabilitation and outpatient services.

Today Kindred Healthcare has 97 transitional care hospitals, 98 nursing centers, 21 sub-acute units, 153 Kindred at Home hospice and home health locations, and 104 inpatient rehabilitation units. RehabCare serves 1,875 non-affiliated facilities.

In November 2021, LifePoint Health and Kindred Healthcare merged and formed a new company ScionHealth. At least 61 Kindred Healthcare locations will be rebranded as ScionHealth.

Headquarters for Kindred and ScionHealth will remain in Louisville, Kentucky.

Kindred Healthcare/ScionHealth

Kindred Healthcare is a healthcare services company that operates nursing homes, hospitals, and rehabilitation centers.

The company was founded in 1985 as Vencor, Inc.

History

Kindred operates in four divisions. The Transitional Care Hospital division provides long-term care to medically complex patients. The Nursing and Rehabilitation Services division operates nursing homes, rehabilitation centers, and assisted living centers.

Care Management provides hospice, home health, and private nursing in patients’ homes. RehabCare is Kindred’s division that provides hospital rehabilitation and outpatient services.

Today Kindred Healthcare has 97 transitional care hospitals, 98 nursing centers, 21 sub-acute units, 153 Kindred at Home hospice and home health locations, and 104 inpatient rehabilitation units. RehabCare serves 1,875 non-affiliated facilities.

In November 2021, LifePoint Health and Kindred Healthcare merged and formed a new company ScionHealth. At least 61 Kindred Healthcare locations will be rebranded as ScionHealth.

Headquarters for Kindred and ScionHealth will remain in Louisville, Kentucky.

Biogen Idec Corporate Office

Biogen Idec is a biotechnology company based in Cambridge, Massachusetts.

The company was founded by prominent biologists Sir Kenneth Murray, Charles Weissmann, and Phillip Sharp in 1978 in Geneva.

Biogen focuses on developing treatments primarily for immunology and neurology. Popular drugs include Avonex, which treats relapsing MS, Tysabrim, a treatment for MS and Crohn’s disease, Rituxan, which treats non-Hodkin’s lymphoma and rheumatoid arthritis, and Fumaden, a treatment for psoriasis.

The company has customers in over 90 countries worldwide.

In March 2020, Biogen employees unwittingly spread the COVID-19 virus from it’s home office in Massachusetts to Indiana, Tennessee, and North Carolina, after a company leadership meeting. 

Company shares also rose in March as investors looked for “safe” places to park their money and ride out the pandemic. 

Biogen Idec trades publicly on the NASDAQ under the ticker symbol BIIB, is a member of the S&P 500, is #375 in the Fortune 500, has 7,300 employees, and had $12.274 billion in revenue in 2017.

Biogen Idec

Biogen Idec is a biotechnology company based in Cambridge, Massachusetts.

The company was founded by prominent biologists Sir Kenneth Murray, Charles Weissmann, and Phillip Sharp in 1978 in Geneva.

History

Biogen focuses on developing treatments primarily for immunology and neurology. Popular drugs include Avonex, which treats relapsing MS, Tysabrim, a treatment for MS and Crohn’s disease, Rituxan, which treats non-Hodkin’s lymphoma and rheumatoid arthritis, and Fumaden, a treatment for psoriasis.

The company has customers in over 90 countries worldwide.

In March 2020, Biogen employees unwittingly spread the COVID-19 virus from it’s home office in Massachusetts to Indiana, Tennessee, and North Carolina, after a company leadership meeting. 

Company shares also rose in March as investors looked for “safe” places to park their money and ride out the pandemic. 

Biogen Idec trades publicly on the NASDAQ under the ticker symbol BIIB, is a member of the S&P 500, is #375 in the Fortune 500, has 7,300 employees, and had $12.274 billion in revenue in 2017.